New generations of targeted therapies fighting the resistance in solid tumorsBarthélémy, Philippea,b; Aftimos, Philippea; Awada, AhmadaCurrent Opinion in Oncology: May 2015 - Volume 27 - Issue 3 - p 243–249 doi: 10.1097/CCO.0000000000000175 INNOVATIVE EARLY CLINICAL TRIALS METHODOLOGY AND NEW THERAPEUTICS IN CANCER: Edited by Ahmad Awada Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review The identification of molecular alterations that drive tumor growth and spread of solid tumors has led to the development of multiple targeted therapies considered as first-generation agents that have improved clinical benefit. However, tumor cells are able to rapidly develop resistance to these agents. The growing understanding of the biology of the resistance mechanisms has spurred ongoing development of second-generation and third-generation targeted therapies aiming at new strategies to overcome resistance. Recent findings Several generations of targeted therapies have been developed in order to prevent, delay or overcome tumor resistance. Some agents have already been approved, and others are currently under active clinical investigation in several cancer subtypes, including breast cancer, nonsmall cell lung cancer, head and neck squamous cell cancer and colorectal cancer. Summary In the present review, we will discuss in solid tumors, the recent development of next generation anticancer-targeted therapies and new strategies including combination agents currently under active clinical investigation. aMedical Oncology Clinic, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium bDépartement d’Oncologie médicale et d’hématologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France Correspondence to Philippe Barthélémy, MD, Département d’Oncologie médicale et d’hématologie, Hôpitaux Universitaires de Strasbourg, 1 place de l’Hôpital, 67091 Strasbourg, France. Tel: +33 3 88 11 58 77; e-mail: firstname.lastname@example.org Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.